Eli Lilly and Company
7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
Last updated:
Abstract:
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I). ##STR00001##
Status:
Application
Type:
Utility
Filling date:
16 Mar 2021
Issue date:
29 Jul 2021